ENDRA Life Sciences Inc. NDRA
4.96 USD +0.10 (+2.06%)
Nov 4, 2026, 3:38 PM EST
4.75 Day range 4.96
2.96 52-week range 6.95
- YTD
- +9.49%
- 1 year
- -0.60%
- Market cap
- 7.44M
- EPS (ttm)
- -6.26
- Shares out
- 536.91K
- Forward P/E
- -0.02
- YTD return
- +9.49%
- 1-year return
- -0.60%
- Volume
- 6.29K
- Avg volume
- 30.65K
- Open
- 4.75
- Previous close
- 4.86
- Day's range
- 4.75 – 4.96
- 52-week range
- 2.96 – 6.95
- Beta
- 0.74
- Price target
- 2,625.00 (+52823.4%)
5D -0.14 (-2.80%)
Key statistics
- Enterprise value
- -5.66M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -2.48M
- Total cash
- 6.40M
- Total debt
- 549.13K
- Return on equity
- -120.13%
- Short % of float
- 4.64%
- 50-day average
- 6.68
- 200-day average
- 291.96
Analyst view
Price target (mean) 2,625.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -143.50.
Financials — quick view
NDRA Revenue — quarterly 0
NDRA Net income — quarterly 159.94K
NDRA EPS — quarterly 0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2024 | Sep 1, 2024 | -62.24 | -5.85 | +56.39 | +90.60% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -139.86 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -454.55 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -297.20 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -699.30 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -751.75 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 7, 2024 | Ascendiant Capital | main | Buy | Buy |
| Mar 31, 2023 | HC Wainwright & Co. | reit | — | Buy |
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- endrainc.com
News
ENDRA Life Sciences (NASDAQ:NDRA) Shares Climb 1.9% – Time to Buy? 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
12 Health Care Stocks Moving In Wednesday's Intraday Session - 12 Health Care Stocks Moving In Wednesday's After-Market Session
ENDRA Life Sciences Q2 EPS $0.06 Beats $(0.84) Estimate 
ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update 
ASP Isotopes Issues Letter to Shareholders - 12 Health Care Stocks Moving In Tuesday's After-Market Session
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company 
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
Your note
Sign in to keep a note on NDRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASENESE LOUIS J. | Director | Sale | Aug 25, 2021 | 49,068 |
| DIGIANDOMENICO ANTHONY | Director | Purchase | May 1, 2023 | 102,434 |
| GAMBHIR SANJIV SAM | Director | Stock Award(Grant) | Apr 8, 2020 | 42,857 |
| HARSH MICHAEL JOHN | Director | Conversion of Exercise of derivative security | Jun 22, 2020 | 69,243 |
| LONGBOARD CAPITAL ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 23, 2018 | 0 |
| MALOBERTI RENAUD BERTRAND | Officer | Sale | Jan 12, 2021 | 1,580 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Virtu Financial LLC | 0.43% | 2,300 | 12.88K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.10% | 549 | 3.07K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.09% | 466 | 2.61K | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.08% | 405 | 2.27K | Sep 29, 2024 |
| HRT Financial LP | 0.07% | 396 | 2.22K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.06% | 320 | 1.79K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.01% | 35 | 195 | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 23 | 128 | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 5 | 27 | Oct 30, 2024 |